Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Sildenafil in Heart failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial: rationale and design.

Cooper TJ, Guazzi M, Al-Mohammad A, Amir O, Bengal T, Cleland JG, Dickstein K.

Eur J Heart Fail. 2013 Jan;15(1):119-22. doi: 10.1093/eurjhf/hfs152. Epub 2012 Oct 24.

2.

Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.

Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, Tawakol A, Gerszten RE, Systrom DM, Bloch KD, Semigran MJ.

Circulation. 2007 Oct 2;116(14):1555-62. Epub 2007 Sep 4.

3.
4.

Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy.

Tay EL, Papaphylactou M, Diller GP, Alonso-Gonzalez R, Inuzuka R, Giannakoulas G, Harries C, Wort SJ, Swan L, Dimopoulos K, Gatzoulis MA.

Int J Cardiol. 2011 Jun 16;149(3):372-6. doi: 10.1016/j.ijcard.2010.02.020. Epub 2010 Mar 20.

PMID:
20304507
5.

Hemodynamic and clinical benefits associated with chronic sildenafil therapy in advanced heart failure: experience of the Montréal Heart Institute.

Potter BJ, White M, Carrier M, Pellerin M, L'Allier PL, Pelletier GB, Racine N, Ducharme A.

Can J Cardiol. 2012 Jan-Feb;28(1):69-73. doi: 10.1016/j.cjca.2011.09.018. Epub 2011 Nov 29.

PMID:
22129489
6.

Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study.

Guazzi M, Vicenzi M, Arena R, Guazzi MD.

Circulation. 2011 Jul 12;124(2):164-74. doi: 10.1161/CIRCULATIONAHA.110.983866. Epub 2011 Jun 27.

7.

Is chronic sildenafil therapy safe and clinically beneficial in patients with systolic heart failure?

Amin A, Mahmoudi E, Navid H, Chitsazan M.

Congest Heart Fail. 2013 Mar-Apr;19(2):99-103. doi: 10.1111/chf.12008. Epub 2012 Dec 12.

8.

Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial.

Behling A, Rohde LE, Colombo FC, Goldraich LA, Stein R, Clausell N.

J Card Fail. 2008 Apr;14(3):189-97. doi: 10.1016/j.cardfail.2007.11.006.

PMID:
18381181
9.

Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship.

Garg N, Sharma MK, Sinha N.

Int J Cardiol. 2007 Sep 3;120(3):306-13. Epub 2006 Dec 15.

PMID:
17174417
10.

Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O'Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E; RELAX Trial.

JAMA. 2013 Mar 27;309(12):1268-77. doi: 10.1001/jama.2013.2024.

11.

Clinical deterioration after sildenafil cessation in patients with pulmonary hypertension.

Keogh AM, Jabbour A, Hayward CS, Macdonald PS.

Vasc Health Risk Manag. 2008;4(5):1111-3.

12.

Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.

Keogh AM, Jabbour A, Weintraub R, Brown K, Hayward CS, Macdonald PS.

J Heart Lung Transplant. 2007 Nov;26(11):1079-83. Epub 2007 Oct 24.

PMID:
18022071
13.

Pulmonary hypertension in heart failure with preserved ejection fraction: a target for therapy?

Waxman AB.

Circulation. 2011 Jul 12;124(2):133-5. doi: 10.1161/CIRCULATIONAHA.111.038885. No abstract available.

15.

Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.

Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB; PACES Study Group.

Ann Intern Med. 2008 Oct 21;149(8):521-30. Erratum in: Ann Intern Med. 2009 Jan 6;150(1):63. Ann Intern Med. 2009 Sep 15;151(6):435.

PMID:
18936500
17.

Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial.

Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Søndergaard L.

Eur Heart J. 2010 May;31(9):1124-31. doi: 10.1093/eurheartj/ehq011. Epub 2010 Mar 3.

PMID:
20202971
19.

Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial.

Hoendermis ES, Liu LC, Hummel YM, van der Meer P, de Boer RA, Berger RM, van Veldhuisen DJ, Voors AA.

Eur Heart J. 2015 Oct 7;36(38):2565-73. doi: 10.1093/eurheartj/ehv336. Epub 2015 Jul 17.

PMID:
26188003
20.

Letter by Jamous regarding article, "Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study".

Jamous FG.

Circulation. 2012 Feb 28;125(8):e407; author reply e409-10. doi: 10.1161/CIRCULATIONAHA.111.066225. No abstract available.

Supplemental Content

Support Center